Medivation (MDVN) : Mondays money flow points at investors jumping to buy the stock on the weakness of price. $8.34 million worth of transactions were on upticks, whereas, the downticks accounted for $6.01 million worth of transactions. The net money flow was a positive $2.34 million and the uptick to downtick ratio was 1.39. The net money flow into the stock was $1.11 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $1.11 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Medivation (MDVN) was trading at $61.79, down $0.09 during day. The stock slid -0.15% over the previous days close. For the week, the stock recorded -0.5% over the previous weeks close.
Medivation, Inc. is up 15.87% in the last 3-month period. Year-to-Date the stock performance stands at 27.91%. Medivation, Inc. has dropped 0.64% in the last five trading days, however, the shares have posted positive gains of 4.16% in the last 4 weeks. In a related news,The officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., Powell Andrew Kenneth William sold 2,578 shares at $60.42 on June 6, 2016. The Insider selling transaction had a total value worth of $155,763. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Medivation (NASDAQ:MDVN): On Mondays trading session , Opening price of the stock was $61.88 with an intraday high of $62.14. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $61.533. However, the stock managed to close at $61.83, a loss of 0.08% for the day. On the previous day, the stock had closed at $61.88. The total traded volume of the day was 702,671 shares.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.